Motely was nowhere to be seen when this stock was under $10. Now that it is at $15, they are pumping. Give us your email, and we'll tell you how to buy high and sell low! I hope no one is selling because of MFI.
This Board has become uncivil after these day-traders have infested this Board. Signs of a looser - calling names, incessant postings (1500 or more per quarter), belief in crazy notions such as correlation between someone's posting and stock price...!!!! For the year you have been daytrading this $2 stock (pre RS), you should have made millions. Why hang around here? Go and enjoy it!
Your visceral reaction to a simple request to tone it down indicates you are a very insecure person. You and your Ouija board buddy should trade emails and converse with each other privately instead of using this board for exchanging messages.
Twice, the stock has been trying to get through 30, and the Ouija board readers have been shorting it. It will close in the 30's today, and the shorts will get burnt.
The European Commission has granted approval to Merck's Keytruda, or pembrolizumab, as a treatment for advanced melanoma. The approval was backed by trial data that showed the drug reduced patients' death risk by 37% and improved one-year survival, compared with Bristol-Myers Squibb's Yervoy, or ipilimumab. PharmaTimes (U.K.) (7/22)